- In December 2020, OMRON Healthcare introduced WheezeScan, a device designed to accurately detect wheezing in children with asthma. This innovative tool helps eliminate the uncertainty associated with potential misdiagnosis, ensuring more precise asthma management in young patients. By offering an easy-to-use solution, WheezeScan aims to improve early detection and treatment outcomes for children affected by asthma
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Metered Dose Inhalers, Dry Powder Inhalers, and Soft Mist Inhalers), Mode of Operation (Manually Operated Inhaler Devices and Digitally-Operated Inhaler Devices), End User (Hospitals & Clinics, Homecare, and Others) – Industry Trends and Forecast to 2032
.
The Global Asthma Inhaler Device Market size was valued at USD 16.50 USD Billion in 2024.
The Global Asthma Inhaler Device Market is projected to grow at a CAGR of 4.11% during the forecast period of 2025 to 2032.
The major players operating in the market include Koninklijke Philips N.V., GlaxoSmithKline plc, AstraZeneca, Cipla, Boehringer Ingelheim International GmbH, Beximco Pharmaceuticals Ltd., Merck Sharp & Dohme Corp., Teva Pharmaceutical Industries Ltd, CHIESI Farmaceutici S.p.A., Lifescience Pvt. Ltd, Medical DepotInc., HEALTH PRODUCTSInc., Invacare Corporation, Omron HealthcareInc., PARI GmbH .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
